Warning Letter — Ketamine Store / www.ketaminestore.org
The FDA issued a warning letter to Ketamine Store for operating a website that distributes unapproved and misbranded drug products. The Center for Drug Evaluation and Research targeted the entity for offering products without approved new drug applications and for marketing prescription drugs directly to consumers.
This affects online drug retailers, distributors of ketamine or related compounds, and regulatory compliance departments overseeing digital health and e-commerce platforms.
This enforcement action underscores the FDA's ongoing monitoring of the online marketplace for controlled substances and unapproved therapies. It suggests that the Agency is prioritizing actions against entities that facilitate the acquisition of potent medications without adequate medical supervision or validated safety and efficacy data.
Regulatory and legal teams should audit online distribution channels to ensure all marketed drug products have valid NDAs or ANDAs. Compliance officers must verify that labeling for prescription drugs is not directed toward consumers in a manner that bypasses practitioner oversight.
FDA Warning Letter issued to: Ketamine Store / www.ketaminestore.org. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ketamine-store-wwwketaminestoreorg-725147-06232026
Open in openFDA / FDA.gov